A randomized phase 2 iPRIME study found that adding durvalumab plus tremelimumab to standard neoadjuvant chemotherapy did not meet the trial’s primary efficacy endpoint in newly diagnosed advanced high-grade serous ovarian cancer. In the Du-T-NACT arm, the rate of CRS 3 after three cycles was 32.5% (90% CI 20%–47%), below the pre-specified target. Radiologic response after treatment was similar between groups based on RECIST 1.1 (45% with immunotherapy vs 50% with chemotherapy alone; p=0.82). Progression-free survival and other secondary endpoints were evaluated for comparison, but the headline result indicates no incremental benefit from the dual checkpoint approach in this setting. The trial enrolled 49 patients in the durvalumab/tremelimumab combination arm, with 40 evaluable for the chemotherapy response score, using an open-label, multicenter design with a 2:1 randomization scheme.